Clinical Trial Results:
A randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors.
Revised protocol 02 incorporating Amendment 02 & 03 & Administrative Letter 01
+ Pharmacogenetics Blood Sample Amendment 01 (version 1.0, dated 28-Jan-2008)
Summary
|
|
EudraCT number |
2008-000087-16 |
Trial protocol |
GB DE NL FR BE |
Global completion date |
26 Mar 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Dec 2016
|
First version publication date |
07 Dec 2016
|
Other versions |
|
Summary report(s) |
CA182-026_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.